EP1178822B1 - Vaccin anticancereux a cellules entieres comprenant des cellules malignes et non-malignes co-cultivees - Google Patents
Vaccin anticancereux a cellules entieres comprenant des cellules malignes et non-malignes co-cultivees Download PDFInfo
- Publication number
- EP1178822B1 EP1178822B1 EP00931400A EP00931400A EP1178822B1 EP 1178822 B1 EP1178822 B1 EP 1178822B1 EP 00931400 A EP00931400 A EP 00931400A EP 00931400 A EP00931400 A EP 00931400A EP 1178822 B1 EP1178822 B1 EP 1178822B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cultured
- malignant
- culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003211 malignant effect Effects 0.000 title claims abstract description 41
- 229940022399 cancer vaccine Drugs 0.000 title claims abstract description 12
- 238000009566 cancer vaccine Methods 0.000 title claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 73
- 229960005486 vaccine Drugs 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 230000005486 microgravity Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 229940030156 cell vaccine Drugs 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 14
- 230000005847 immunogenicity Effects 0.000 claims description 14
- 238000003306 harvesting Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 8
- 230000001464 adherent effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000004115 adherent culture Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 238000003501 co-culture Methods 0.000 abstract description 66
- 239000006285 cell suspension Substances 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 10
- 210000000987 immune system Anatomy 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 251
- 241000700159 Rattus Species 0.000 description 71
- 210000004881 tumor cell Anatomy 0.000 description 42
- 210000002950 fibroblast Anatomy 0.000 description 32
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 230000012010 growth Effects 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000002243 precursor Substances 0.000 description 20
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000012595 freezing medium Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 210000005267 prostate cell Anatomy 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002123 RNA extraction Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 210000002536 stromal cell Anatomy 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000007790 scraping Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000016911 Deoxyribonucleases Human genes 0.000 description 8
- 108010053770 Deoxyribonucleases Proteins 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 229930182816 L-glutamine Natural products 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 description 6
- 238000011613 copenhagen rat Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000000955 neuroendocrine Effects 0.000 description 6
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 5
- 102100037904 CD9 antigen Human genes 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 102100038884 Major vault protein Human genes 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 229950004398 broxuridine Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- -1 poly(ADP-ribose) Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102100027831 14-3-3 protein theta Human genes 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 108090000669 Annexin A4 Proteins 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 4
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 4
- 102100034294 Glutathione synthetase Human genes 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 102100037599 SPARC Human genes 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 3
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 3
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 102000004148 Annexin A4 Human genes 0.000 description 3
- 102100034273 Annexin A7 Human genes 0.000 description 3
- 108010039940 Annexin A7 Proteins 0.000 description 3
- 102100032412 Basigin Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 3
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 3
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 description 3
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 3
- 102000000802 Galectin 3 Human genes 0.000 description 3
- 108010001517 Galectin 3 Proteins 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 3
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 3
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 description 3
- 101000662690 Homo sapiens Trafficking protein particle complex subunit 10 Proteins 0.000 description 3
- 102100026819 Inositol polyphosphate 1-phosphatase Human genes 0.000 description 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 3
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 3
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 3
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 3
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 102100037456 Trafficking protein particle complex subunit 10 Human genes 0.000 description 3
- 102100035054 Vesicle-fusing ATPase Human genes 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000012342 propidium iodide staining Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001768 subcellular fraction Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 2
- 101710108995 14-3-3 protein theta Proteins 0.000 description 2
- 102100037710 40S ribosomal protein S21 Human genes 0.000 description 2
- 101710164309 56 kDa type-specific antigen Proteins 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 108010025614 Apolipoproteins D Proteins 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 2
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- 102100031171 CCN family member 1 Human genes 0.000 description 2
- 101710137355 CCN family member 1 Proteins 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 2
- 108010010919 Casein Kinase II Proteins 0.000 description 2
- 102000052052 Casein Kinase II Human genes 0.000 description 2
- 101710099573 Casein kinase II subunit alpha Proteins 0.000 description 2
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 description 2
- 101710159482 Casein kinase II subunit alpha' Proteins 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010014080 DNA Polymerase gamma Proteins 0.000 description 2
- 101710169135 Eburicol 14-alpha-demethylase Proteins 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 108010036164 Glutathione synthase Proteins 0.000 description 2
- 101710101434 Glutathione synthetase Proteins 0.000 description 2
- 101710087514 Glutathione synthetase, chloroplastic Proteins 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 102100030338 Hexokinase-1 Human genes 0.000 description 2
- 101710198391 Hexokinase-1 Proteins 0.000 description 2
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 2
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 description 2
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 description 2
- 101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 description 2
- 101001034527 Homo sapiens Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 2
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 2
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- 101710204480 Lysosomal acid phosphatase Proteins 0.000 description 2
- 101710094960 Major vault protein Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010093163 Member 3 Group A Nuclear Receptor Subfamily 4 Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 2
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 2
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 2
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 description 2
- 102000003789 Nuclear pore complex proteins Human genes 0.000 description 2
- 108090000163 Nuclear pore complex proteins Proteins 0.000 description 2
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 description 2
- 102100032138 Nucleolysin TIAR Human genes 0.000 description 2
- 101710171971 Nucleolysin TIAR Proteins 0.000 description 2
- 101710086167 Obtusifoliol 14-alpha demethylase Proteins 0.000 description 2
- 108010077077 Osteonectin Proteins 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 102100034763 Peroxiredoxin-2 Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 101710148394 Probable lanosterol 14-alpha demethylase Proteins 0.000 description 2
- 102100033954 Protein PRRC2A Human genes 0.000 description 2
- 102100023087 Protein S100-A4 Human genes 0.000 description 2
- 102100032733 Protein jagged-2 Human genes 0.000 description 2
- 101710170213 Protein jagged-2 Proteins 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 102100030705 Ras-related protein Rap-1b Human genes 0.000 description 2
- 101710116844 Ras-related protein Rap-1b Proteins 0.000 description 2
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 description 2
- 101710100111 SPARC Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000003711 Syndecan-2 Human genes 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- 102100024174 Syntaxin-7 Human genes 0.000 description 2
- 102100038618 Thymidylate synthase Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102100040761 Zinc finger and BTB domain-containing protein 17 Human genes 0.000 description 2
- 102100029504 Zinc finger protein RFP Human genes 0.000 description 2
- 101710110903 Zinc finger protein RFP Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108010008429 immunoglobulin-binding factors Proteins 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108010028069 procathepsin B Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 2
- 108010092936 ribosomal protein S21 Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000005477 standard model Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001709 templated self-assembly Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 102100023779 40S ribosomal protein S5 Human genes 0.000 description 1
- 101710107635 40S ribosomal protein S5 Proteins 0.000 description 1
- 101710187296 60S ribosomal protein L10 Proteins 0.000 description 1
- 102100040430 Active breakpoint cluster region-related protein Human genes 0.000 description 1
- 101710090794 Active breakpoint cluster region-related protein Proteins 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 1
- 101710168921 Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 102000009333 Apolipoprotein D Human genes 0.000 description 1
- 102100022954 Apolipoprotein D Human genes 0.000 description 1
- 101000728594 Arabidopsis thaliana 40S ribosomal protein Sa-1 Proteins 0.000 description 1
- 101100244969 Arabidopsis thaliana PRL1 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000051618 BRCA1-associated protein Human genes 0.000 description 1
- 108700039023 BRCA1-associated protein Proteins 0.000 description 1
- 108010064528 Basigin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010063916 CD40 Antigens Proteins 0.000 description 1
- 101000951607 Caenorhabditis elegans Peptidyl-prolyl cis-trans isomerase 3 Proteins 0.000 description 1
- 102000003895 Calpain-1 Human genes 0.000 description 1
- 108090000236 Calpain-1 Proteins 0.000 description 1
- 101001024441 Candida albicans (strain SC5314 / ATCC MYA-2876) Major facilitator superfamily multidrug transporter NAG3 Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102100021633 Cathepsin B Human genes 0.000 description 1
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 description 1
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102100022785 Creatine kinase B-type Human genes 0.000 description 1
- 101710124411 Creatine kinase B-type Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 102100034025 Cytohesin-1 Human genes 0.000 description 1
- 102100034031 Cytohesin-2 Human genes 0.000 description 1
- 102000016903 DNA Polymerase gamma Human genes 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 101710162625 DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 101000636084 Drosophila melanogaster 40S ribosomal protein SA Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150093300 EPX gene Proteins 0.000 description 1
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 102000012085 Endoglin Human genes 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108050002855 Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000723509 Homo sapiens 14-3-3 protein sigma Proteins 0.000 description 1
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 1
- 101000859448 Homo sapiens Beta/gamma crystallin domain-containing protein 1 Proteins 0.000 description 1
- 101000934351 Homo sapiens CD302 antigen Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101100273813 Homo sapiens CDKN1A gene Proteins 0.000 description 1
- 101000892026 Homo sapiens Casein kinase II subunit alpha Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101000870120 Homo sapiens Cytohesin-2 Proteins 0.000 description 1
- 101100225644 Homo sapiens ELF3 gene Proteins 0.000 description 1
- 101001054823 Homo sapiens Inositol polyphosphate 1-phosphatase Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101000663639 Homo sapiens Kunitz-type protease inhibitor 2 Proteins 0.000 description 1
- 101100454448 Homo sapiens LGALS3 gene Proteins 0.000 description 1
- 101001039189 Homo sapiens Leucine-rich repeat-containing protein 17 Proteins 0.000 description 1
- 101001001294 Homo sapiens Lysosomal acid phosphatase Proteins 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 101000929655 Homo sapiens Monoacylglycerol lipase ABHD2 Proteins 0.000 description 1
- 101000583057 Homo sapiens NGFI-A-binding protein 2 Proteins 0.000 description 1
- 101000925651 Homo sapiens Protein ENL Proteins 0.000 description 1
- 101001068634 Homo sapiens Protein PRRC2A Proteins 0.000 description 1
- 101000926083 Homo sapiens Rab GDP dissociation inhibitor beta Proteins 0.000 description 1
- 101001132658 Homo sapiens Retinoic acid receptor gamma Proteins 0.000 description 1
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 description 1
- 101000652300 Homo sapiens Synaptosomal-associated protein 23 Proteins 0.000 description 1
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 1
- 101000964478 Homo sapiens Zinc finger and BTB domain-containing protein 17 Proteins 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 101710133957 Inositol polyphosphate 1-phosphatase Proteins 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 1
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108010065958 Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 description 1
- 102100027665 Isopentenyl-diphosphate Delta-isomerase 1 Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010070507 Keratin-7 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102100039020 Kunitz-type protease inhibitor 2 Human genes 0.000 description 1
- 101000643952 Lacticaseibacillus rhamnosus Uridine phosphorylase Proteins 0.000 description 1
- 102100040690 Leucine-rich repeat-containing protein 17 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 1
- 101710092458 Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 101150051246 MAC2 gene Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 1
- 101100509424 Mus musculus Itsn1 gene Proteins 0.000 description 1
- 101000707216 Mus musculus SH2 domain-containing protein 1B2 Proteins 0.000 description 1
- 101100420730 Mus musculus Sec23a gene Proteins 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 108010075393 Myeloid-Lymphoid Leukemia Protein Proteins 0.000 description 1
- 108010081735 N-Ethylmaleimide-Sensitive Proteins Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710130886 Protein PRRC2A Proteins 0.000 description 1
- 102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 1
- 101710081954 Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 1
- 101710151339 Protein transport protein SEC23 Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010014651 Proto-Oncogene Protein c-ets-1 Proteins 0.000 description 1
- 102000017012 Proto-Oncogene Protein c-ets-1 Human genes 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 102100034328 Rab GDP dissociation inhibitor beta Human genes 0.000 description 1
- 102100027838 Ras-related protein Rab-31 Human genes 0.000 description 1
- 101710113710 Ras-related protein Rab-31 Proteins 0.000 description 1
- 102100027915 Ras-related protein Rab-32 Human genes 0.000 description 1
- 101710113704 Ras-related protein Rab-32 Proteins 0.000 description 1
- 102100025337 Reticulocalbin-2 Human genes 0.000 description 1
- 101710164377 Reticulocalbin-2 Proteins 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 101150080918 SEC23 gene Proteins 0.000 description 1
- 108091006627 SLC12A9 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 description 1
- 101710157194 Serine/threonine-protein phosphatase PP1-gamma Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100030545 Synaptosomal-associated protein 23 Human genes 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 108010077673 Tetraspanin 29 Proteins 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 101710094130 Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 description 1
- 101710101311 Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 description 1
- 108010019092 Uridine phosphorylase Proteins 0.000 description 1
- 102100020892 Uridine phosphorylase 1 Human genes 0.000 description 1
- 101710138514 Vesicle-fusing ATPase Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 101710096191 Zinc finger and BTB domain-containing protein 17 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940038872 cell-based cancer vaccine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 108010036401 cytohesin-1 Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000659 freezing mixture Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010024200 inositol-1,4-bisphosphate 1-phosphatase Proteins 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010090646 preprocathepsin B Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
Definitions
- New vaccines for use as immunotherapeutic agents in the treatment of cancer are described.
- First generation whole cell vaccines relied on traditional methodologies in the culture and production of the autologous or allogeneic cell based vaccines, whereby autologous tumour cells or immortalised allogeneic tumour cell lines were cultured in static two dimensional (2D) culture conditions.
- This invention relates to a co-culture techniques which leads to significant enhancement of the phenotype of cell lines towards a more in vivo phenotype resulting in a vaccine reflecting a more realistic phenotypic representation of an in vivo tumour.
- We describe alternative culture techniques which offer significant scale up and processing benefits and in addition significantly improve the activity of the whole-cell vaccine.
- vaccines produced by the various co-culture techniques described have additional advantages over single cell suspension vaccines in the mode of presentation to the immune system which leads to enhanced performance in treating the disease.
- cancerous cells contain numerous mutations, qualitative and quantitative, spatial and temporal, relative to their non-malignant, non-cancerous counterparts and that at certain periods during tumour growth and spread a proportion of the cancerous cells are capable of being recognised by the host's immune system as abnormal.
- Cancer cells express certain tumour-specific antigens (TSA) and tumour-associated antigens (TAA) that may serve as markers or targets for the immune system.
- TSA tumour-specific antigens
- TAA tumour-associated antigens
- Tumours have the remarkable ability to counteract the immune system in a variety of ways which may include: down-regulation of the expression of potential target proteins; mutation of potential target proteins; down-regulation of surface expression of receptors and other proteins; down-regulation of MHC class I and II expression thereby disallowing direct presentation of TAA or TSA peptides; down-regulation of co-stimulatory molecules leading to incomplete stimulation of T-cells leading to anergy; shedding of selective, non representative membrane portions to act as decoy to the immune system; shedding of selective membrane portions to anergise the immune system; secretion of inhibitory molecules; induction of T-cell death; and many other ways.
- Cell-based vaccines fall into two categories. The first, based on autologous cells, involves the removal of a biopsy from a patient, cultivating tumour cells in vitro , modifying the cells through transfection and/or other means, irradiating the cells to render them replication-incompetent and then injecting the cells back into the same patient as a vaccine. Although this approach enjoyed considerable attention over the past decade, it has been increasingly apparent that this individually-tailored therapy is inherently impractical for several reasons.
- tumour biopsy used to prepare the autologous vaccine will have certain growth characteristics, interactions and communication with surrounding tissue that makes it somewhat unique.
- the second type of cell-based vaccine describes the use of allogeneic cells which are be genetically (and hence immunologically) mismatched to the patients. Allogeneic cells benefit from the same advantages of multivalency as autologous cells. In addition, as allogeneic cell vaccines can be based on immortalised cell lines which can be cultivated indefinitely in vitro, this approach does not suffer the lead-time and cost disadvantages of autologous approaches. Similarly the allogeneic approach offers the opportunity to use combinations of cells types which may match or anticipate the disease profile of an individual in terms of stage of the disease, the location of the lesion and potential resistance to other therapies.
- 2D culture - cells grown in static plastic flasks within incubators, with or without CO 2 atmospheric supplementation
- the cells grow in two dimensions only as a flat monolayer or sheet of cells adherent to the plastic or glass vessel. Cell growth usually becomes contact inhibited at confluence and attempts to grow the cells beyond this point usually results in the loss of the culture.
- the growth of cells in 2D culture relies on the serial passage of cells, wherein the cells are repeatedly removed from the substratum and subjected to a harsh cycle of centrifugation, washing and manipulation in suspension.
- the cells are grown and then harvested by mechanical means or treatment with trypsin to remove the cells from the substratum.
- trypsin other proteolytic enzymes or other agents used for the purpose is to break attachment of the cells to the flask substrate.
- Proteolytic treatment inevitably removes some protein molecules from the surface of the cells, which may result in loss of potential epitopes that enable the recipient to raise an humoral or cell based immune response to the tumour.
- proteolysis may remove MHC-I molecules that could present peptides in a direct manner to patient T cells, or adhesion molecules that offer co-stimulatory activity to direct presentation.
- proteolysis may simply remove aberrantly expressed TAA or TSA which when processed through a cross-priming or other route could also contribute to an anti-tumour response.
- TAA or TSA which when processed through a cross-priming or other route could also contribute to an anti-tumour response.
- proteolysis may simply remove aberrantly expressed TAA or TSA which when processed through a cross-priming or other route could also contribute to an anti-tumour response.
- there is relatively little opportunity to manipulate the cell phenotype since, in order to attain the quantity of cells required, a number of passages under standard growth conditions are required and attempts to drive the cells into a stressed or apoptotic or necrotic or otherwise altered phenotype prior to harvest results in significant losses of fragile cells at harvest undermining the feasibility of producing vaccine at a practical scale.
- Hitherto described cell based cancer vaccines are based on i) populations of primary cultures of autologous tumour cells; ii) single populations of allogeneic immortalised tumour cell lines; iii) allogeneic immortalised cell lines as many as three or four in combination and iv) genetically modified fibroblasts in combination with tumour cells.
- WO/99 19462. discloses a whole cell cancer vaccine wherein the malignant cells are cultured with other non-malignant cells. This results in a vaccine in which the non-malignant cells have an enhanced cytokine secretion and co-stimulatory molecules expression, which renders the whole cell vaccine more effective.
- the present invention describes culture methods for large scale production of vaccines; phenotype adjustment of established cell lines; co-culture techniques; specific compositions of immortalised tumour cell lines and immortalised non-malignant cells; compositions comprising immortalised tumour cells and autologous non-malignant cells; processing methods for the production of the vaccines; analytical techniques to evaluate phenotype adjustment and new compositions which display increased immunogenicity in standard models of tumour prevention and therapy.
- this invention describes a new strategy, targeting the immune response not only to the tumour itself but also to the local tumour environment and the non-malignant cells which comprise that environment.
- tumour cells are intensely immunosuppressive where all facets of immune surveillance are inhibited, from inhibition of T cell and antigen presenting cell (APC) migration, to inhibition of APC maturation and induction of T cell anergy.
- APC antigen presenting cell
- Many of the immunosuppressive activities found in the immediate local tumour environment are mediated by soluble factors released by the tumour cells, such as IL-10 and TGF ⁇ .
- soluble factors released by the tumour cells such as IL-10 and TGF ⁇ .
- Tumour-adjacent cells are induced to secrete or express enhanced levels of receptors or other proteins (e.g.
- tumour-adjacent non-malignant cells are aberrant to distant non-malignant cells in that they are induced to express proteins that distant counterparts do not; this will be reflected in a qualitatively and/or quantitatively modified spectrum of peptides displayed on the tumour-adjacent cells MHC-I molecules which can be recognised by the immune system as aberrant.
- this embodiment targets the local tumour micro-environment in addition to the tumour itself.
- This embodiment describes the preparation of a mixed cell type vaccine, in which tumour cell lines are grown in intimate contact with a non-malignant component.
- the growth of this mixed cell type vaccine can be achieved by a number of means, for example co-culture in 2D flasks, growth in transwell inserts where conditioned medium exerts its effect on the tumour line or growth in a 3D mixed culture system.
- There are significant benefits to a mixed culture approach in that the literature reports that in many cases celi-ceil contact is required to elicit reciprocal phenotypic changes in both tumour and non-tumour components (e.g. Fibroblast mediated differentiation in human breast carcinoma cells (MCF-7) grown as nodules in vitro , Int. J.
- MCF-7 human breast carcinoma cells
- This invention describes the use of 3D microgravity culture to grow significant quantities of tumour cells and co-cultured cells for use as vaccines.
- a 500 ml 3D microgravity vessel we can achieve the same vaccine production of mammalian tumour cell lines as we could obtain by culturing 300 T175 flasks or 30 1,700 cm 2 roller bottles.
- a further embodiment of this invention is the use of 3D co-culture to achieve a mixed cell type vaccine comprising an immortalised tumour cell line in combination with an immortalised or non-immortalised non-malignant cell line such as epithelial cells, stromal fibroblasts, bone stromal cells, endothelial cells, palisade cells or any other immortalised or non immortalised non-malignant cell type.
- an immortalised or non-immortalised non-malignant cell line such as epithelial cells, stromal fibroblasts, bone stromal cells, endothelial cells, palisade cells or any other immortalised or non immortalised non-malignant cell type.
- an immortalised or non-immortalised non-malignant cell line such as epithelial cells, stromal fibroblasts, bone stromal cells, endothelial cells, palisade cells or any other immortalised or non immortalised non-malignant cell type.
- an immortalised or non-immortalised non-malignant cell line
- Two immortalised neuroendocrine tumour lines are known in the literature, the prostatic derived lung metastatic neuroendocrine line CRL5813 (NCI-H660) and the colorectal neuroendocrine line COLO320DMF, both of which secrete neuroendocrine factors such as parathyroid hormone, bombesin, etc.
- the cultures may be co-seeded with two or more cell types taken from independent 2D culture flasks, or the culture may be sequentially seeded for example with a stromal fibroblast first, followed some one or two days later by a tumour cell line.
- a further aspect of this invention is a direct process of formulation of cells harvested from 3D microgravity culture without the need to treat the cells with trypsin. This process therefore has the advantage of significantly increasing the yield of cells following harvest, whereas for traditionally grown 2D cultures significant losses are incurred during the trypsinization, neutralization, washing and formulation. Cells harvested as spheroids tend to be significantly more robust to handle and wash, thereby leading to enhanced recoveries.
- a further embodiment of this invention is the use of mixed 3D microgravity culture incorporating non-malignant cell lines to enhance the phenotype of cell lines which hitherto have not been grown in mixed 3D culture.
- a further embodiment of this invention is enhanced immunogenicity arising from the use of non-malignant cells in combination with tumour cell lines arising from direct presentation of peptides on the MHC-I molecules of the non-malignant cell line, particularly if the non-malignant cell line is matched or partially matched to the recipient.
- the peptides may be released from the tumour cell lines during growth, processing and irradiation of the 3D cell mass, or may be released during initial interaction of macrophages and dendritic cells at the time of injection.
- a separate embodiment of this invention is the use of peptide extracts and other sub-cellular fractions derived from cells and co-cultures of cells grown under non-standard conditions. This includes cells grown on roller bottles, on microcarriers, on polyester fibre discs, 3D culture on non adherent flasks and 3D culture under microgravity conditions.
- the sub-cellular fractions or peptide fractions derived from the cells offer the opportunity to significantly increase the active component of a given vaccine.
- This aspect of the invention also allows for further fractionation of the sub-cellular fractions or peptides to select the active principles and to simplify the vaccine composition if so required.
- a further embodiment of this invention is the production, composition and use of a mixed autologous / allogeneic cell vaccine comprising autologous non-malignant cells taken from an intended recipient of the vaccine grown in culture with an allogeneic immortalised tumour cell line.
- the autologous non-malignant cells have non-malignant levels of MHC-I and will thus have the capability of presenting in the context of autologous MHC-I peptides released from lysed, destroyed or apoptotic tumour cells with which they have been grown.
- the murine melanoma cell line K1735 was grown with the murine fibroblast cell line 3T3 at a ratio of 1:1.
- the 3T3 cells were seeded at 5 x 10 6 cells in a 50 ml cassette for a microgravity instrument (Synthecon) and allowed to grow for 2 days in DMEM 2% foetal calf serum, 10 mM glutamine.
- a further inoculum of 5x10 6 cells of either K1735 was made into the 50 ml rotating cassette (Synthecon) and the culture inoculated for a further 6-9 days.
- the resulting spheroids were harvested and washed by light centrifugation in DMEM at day 8-11 and taken for further analysis.
- the human prostatic epithelial tumour line NIH1542 was grown with the non-malignant human prostatic epithelial line PNT2-C2 at a 1:1 ratio in a 3D microgravity culture vessel (Synthecon).
- the cell lines were co-inoculated at 5x10 6 cells each and cultured in KSFM for a period of 6-11 days until a significant biomass of spheroids had accumulated.
- the cell mass was harvested and washed in serum free medium and then trypsinized to prepare the sample for analysis.
- the human prostatic epithelial tumour line NIH1542 was grown with the human prostatic neuroendocrine epithelial line CRL-5813 at a 1:1 ratio in a 3D microgravity culture vessel (Synthecon).
- the cell lines were co-inoculated at 5x10 6 cells each and cultured in KSFM for a period of 6-11 days until a significant biomass of spheroids had accumulated. ).
- two separate 2D cultures were seeded and grown to near confluence.
- the cells were trypsinized and the mixture of cells from 2D and 3D co-culture were analyzed for the level of apoptosis by annexin and propidium iodide staining and. also for phenotypic expression of various markers.
- the murine melanoma cell line K1735 was grown with the murine fibroblast cell line 3T3 at a ratio of 1:1.
- the 3T3 cells were seeded at 5 x 10 6 cells in a 50 ml cassette for a microgravity instrument (Synthecon) and allowed to grow for 2 days in DMEM 2% foetal calf serum, 10 mM glutamine.
- a further inoculum of 5x10 6 cells of either K1735 was made into the 50 ml rotating cassette (Synthecon) and the culture inoculated for a further 6-9 days.
- the cells were allowed to grow for a period of 7-14 days with intermediate media and growth factor replenishment.
- the cassette was emptied into a centrifuge vessel and lightly centrifuged to pellet the biomass.
- the visible and invisible spheroids were washed three times in PBS or other inert media, irradiated at 50-300 Gy and then either used directly in the protection experiment or; formulated in appropriate freezing mixture (10% DMSO in Hanks) and aliquoted on the basis of either cell number determined by trypsinization and counting or on a protein or nucleic acid basis. No trypsinization was required to remove the vaccine cells from the culture vessel thereby retaining valuable TAA and TSA which will elicit an anti-tumour response in the recipient mammal.
- the spheroids are significantly easier to harvest as a result of their size, requiring less aggressive centrifugation than is normally required for individual cells which leads to significant enhancement of the recovered cell mass.
- mice Groups of 8 C57/B6 mice were immunized with 1-10 x10 6 K1735 / 3T3 spheroids and compared to 2D flask grown K1735 cells irradiated at 150 Gy, at T-10 days. The mice were then challenged on Day 0 with 5x10 5 live B16F10 cells and then monitored for tumour growth.
- Cell lines ONYCAP-1, ONYCAP-23, P4E6 and SHMAC-4 were seeded at 1 x 10 6 cells onto confluent monolayers of NHBMSC cells in T175 culture flasks. Co-cultures were maintained for 2 days using keratinocyte growth medium supplemented with 5% foetal calf serum. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- Onycap1 and Onycap 23 have been deposited under the Budapest Treaty at ECACC on 28 March 2000 under the Accession numbers 00032802 and 00032801 respectively.
- a double extraction was performed using TRI REAGENT (Sigma #T9424).
- the reagent was added directly to the washed cell pellets and samples were allowed to stand for 5 minutes before the addition of chloroform. Samples were vortexed and allowed to stand for a further 10 minutes at room temperature then centrifuged at 12,000xg for 15 minutes.
- RNA precipitated with isopropanol RNA pellets were washed with 75% ethanol, dried and re-suspended in TE buffer.
- RNA sample was treated with Deoxyribonuclease I (Life Technologies #18068-015) to ensure there was no contamination with genomic DNA. Reactions were incubated for 15 minutes at room temperature then the DNase inactivated by the addition of 25mM EDTA and heating to 65°C for 10 minutes.
- Reverse transcription was performed using the 1st strand cDNA synthesis kit for RT-PCR (AMV) from Boehringer Mannheim (#1 483 188). Reactions were incubated at 25°C for 10 minutes then at 42°C for 1 hour. The AMV enzyme was denatured by heating to 99°C for 5 minutes then the reaction was cooled to 4°C.
- AMV 1st strand cDNA synthesis kit for RT-PCR
- PCR primers were designed from published sequences. Verification of cDNA integrity was achieved by PCR amplification using GapdH housekeeping primers. Amplification reactions with the external primer set were carried out using thermocycler program (1). The internal nested PCR set was run on program (2) below.
- the PCR samples were run in pairs.
- the prostate cells alone then the same cells grown in co-culture with NHBMSC followed by NHBMSC alone then a positive and negative control Figure 1.
- PSA expression was not detected in 3 out of 4 prostate cells grown alone however, cDNA isolated from all of the cell lines grown in co-culture with NHBMSC produced a band at 200bp following 2 rounds of PCR amplification suggesting an up-regulation of PSA as a result of co-culture with bone marrow stromal cells.
- Cell line ONYCAP-23 were seeded at 1 x 10 6 cells onto confluent monolayers of NHBMSC cells in T175 culture flasks. Co-cultures were maintained for 2 days using keratinocyte growth medium supplemented with 5% foetal calf serum. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- a double extraction was performed using TRI REAGENT (Sigma #T9424).
- the reagent was added directly to the washed cell pellets and samples were allowed to stand for 5 minutes before the addition of chloroform. Samples were vortexed and allowed to stand for a further 10 minutes at room temperature then centrifuged at 12,000xg for 15 minutes.
- RNA precipitated with isopropanol RNA pellets were washed with 75% ethanol, dried and re-suspended in TE buffer.
- RNA sample was treated with Deoxyribonuclease I (Life Technologies #18068-015) to ensure there was no contamination with genomic DNA. Reactions were incubated for 15 minutes at room temperature then the DNase inactivated by the addition of 25mM EDTA and heating to 65°C for 10 minutes.
- Reverse transcription was performed using the 1st strand cDNA synthesis kit for RT-PCR (AMV) from Boehringer Mannheim (#1 483 188). Reactions were incubated at 25°C for 10 minutes then at 42°C for 1 hour. The AMV enzyme was denatured by heating to 99°C for 5 minutes then the reaction was cooled to 4°C.
- AMV 1st strand cDNA synthesis kit for RT-PCR
- PSA PCR primers were designed from published sequences tabulated below. Verification of cDNA integrity was achieved by PCR amplification using GapdH housekeeping primers. Amplification reactions with the external primer set were carried out using thermocycler program (1). The internal nested PCR set was run on program (2) below.
- thermocycler program was given below and were run on the thermocylcer
- PCR samples were run in pairs on agarose gels.
- tumour elicited stroma shows aberrant expression of proteins in response to the tumour cells.
- K1735 (P25) cells were grown in RPMI 1640 medium supplemented with 10% FCS and 2 mM L-glutamine, trypsinised, irradiated at 100 Gy and formulated into 10%DMSO in RPMI at a cell density of 5x106 cells / ml prior to cryopreservation at -1800C.
- a K1735 tumour grown in a C3H mouse was excised and chopped into small pieces before being forced through a 70um gauze, irradiated at 100 Gy and formulated in 10%DMSO in RPMI at a cell density of 5x106 cells / ml, then cryopreserved at -1800C.
- B16.F10 mouse melanoma clone G10 was grown in RPMI 1640 medium supplemented with 10% FCS and 2 mM L-glutamine, trypsinised and used to inoculate groups of 5 C57BL6 mice at a viable dose of 1x104 cells in 200ul of medium. Three days following viable tumour challenge the mice were dosed with 1x106 of either in vitro grown K1735 or in vivo grown tumour or PBS injected mice and subsequently on three other occasions on days 6 10 and 13 post tumour challenge. Tumour volume and survival were measured (sacrifice when tumour attained 15x15mm) at three day intervals starting at day 11 post tumour challenge.
- Cell line DU145 was seeded at 1 x 10 6 cells onto confluent monolayers of normal human prostatic stromal fibroblasts (NHPSF) in T175 culture flasks. Co-cultures were maintained for 2 days using in MEM medium supplemented with 10% FCS and 2 mM L-glutamine. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- NHSF normal human prostatic stromal fibroblasts
- Normal human prostatic stromal fibroblasts were grown to confluency in a T175 flask in MEM medium supplemented with 10% FCS and 2 mM L-glutamine.
- Cell line DU145 was seeded at 1 x 10 6 cells into T175 flasks and grown in MEM medium supplemented with 10% FCS and 2 mM L-glutamine and grown to confluency. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- a double extraction was performed using TRI REAGENT (Sigma #T9424).
- the reagent was added directly to the washed cell pellets and samples were allowed to stand for 5 minutes before the addition of chloroform. Samples were vortexed and allowed to stand for a further 10 minutes at room temperature then centrifuged at 12,000xg for 15 minutes.
- RNA precipitated with isopropanol RNA pellets were washed with 75% ethanol, dried and re-suspended in TE buffer.
- RNA sample was treated with Deoxyribonuclease I (Life Technologies #18068-015) to ensure there was no contamination with genomic DNA. Reactions were incubated for 15 minutes at room temperature then the DNase inactivated by the addition of 25mM EDTA and heating to 65°C for 10 minutes.
- Labelled cDNA was used to probe a Clontech AtlasTM array (human cancer array II) following the manufacturers protocol for hybridisation and washing. Images were recorded utilising a phosphor imager and recorded files analysed with the Clontech Atlas ImageTM software.
- tumour cell lines which are up or down regulated by growth of tumour cell lines on stromal cells from various organ compartments.
- tumour cell lines with varying degrees of invasivity or metastatic capability in combination with stromal cells such as prostatic fibroblasts, bone stromal fibroblasts, or endothelial cells it is possible to identify significant genes which are temporally and spatially expressed as a result of the intimate contact between tumour and stromal cell and thus enable the identification of antigens which are thus meaningful and viable potential targets for immunotherapy or other therapeutic strategies.
- Cell line DU145 was seeded at 1 x 10 6 cells onto confluent monolayers of normal human bone stromal fibroblasts (NHBSF) in T175 culture flasks. Co-cultures were maintained for 2 days using in MEM medium supplemented with 10% FCS and 2 mM L-glutamine. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- NHSF normal human bone stromal fibroblasts
- Normal human bone stromal fibroblasts were grown to confluency in a T175 flask in MEM medium supplemented with 10% FCS and 2 mM L-glutamine. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- Cell line DU145 was seeded at 1 x 10 6 cells into T175 flasks and grown in MEM medium supplemented with 10% FCS and 2 mM L-glutamine and grown to confluency. Cells were harvested by scraping from the surface of the plastic and washed in Hanks balanced salt solution before RNA extraction.
- a double extraction was performed using TRI REAGENT (Sigma #T9424).
- the reagent was added directly to the washed cell pellets and samples were allowed to stand for 5 minutes before the addition of chloroform. Samples were vortexed and allowed to stand for a further 10 minutes at room temperature then centrifuged at 12,000xg for 15 minutes.
- RNA precipitated with isopropanol RNA pellets were washed with 75% ethanol, dried and re-suspended in TE buffer.
- RNA sample was treated with Deoxyribonuclease I (Life Technologies #18068-015) to ensure there was no contamination with genomic DNA. Reactions were incubated for 15 minutes at room temperature then the DNase inactivated by the addition of 25mM EDTA and heating to 65°C for 10 minutes.
- Reverse transcription was performed using the 1st strand cDNA synthesis kit for RT-PCR (AMV) from Boehringer Mannheim (#1 483 188). Reactions were incubated at 25°C for 10 minutes then at 42°C for 1 hour. The AMV enzyme was denatured by heating to 99°C for 5 minutes then the reaction was cooled to 4°C. 32P or 33P deoxynucleotides were used to label the cDNA for subsequent probing of the arrays. RNA from DU145 and NHBSF cultures were mixed in equal proportions and the same quantity of RNA used in the reverse transcription as was used for the co-culture RNA.
- AMV 1st strand cDNA synthesis kit for RT-PCR
- Labelled cDNA was used to probe a Clontech AtlasTM array (human array II) following the manufacturers protocol for hybridisation and washing. Images were recorded utilising a phosphor imager and recorded files analysed with the Clontech Atlas ImageTM software.
- tumour cell lines which are up or down regulated by growth of tumour cell lines on stromal cells from various organ compartments.
- tumour cell lines with varying degrees of invasivity or metastatic capability in combination with stromal cells such as prostatic fibroblasts, bone stromal fibroblasts, or endothelial cells it is possible to identify significant genes which are temporally and spatially expressed as a result of the intimate contact between tumour and stromal cell and thus enable the identification of antigens which are thus meaningful and viable potential targets for immunotherapy or other therapeutic strategies.
- Results are shown for patient numbers 1, 2, 3, and 4 who had received a series of vaccinations with human prostate cell lines, PNT-2, NIH1542, DU145 and LnCap in a clinical trial to evaluate the safety and immunogenicity of these cell lines.
- Results are given for cell lysates namely, NIH1542, LnCap, DU-145, PNT-2 and also a co-culture of DU145 and NHBSF celis in such a way that the same cell number equivalent is used in each proliferation assay.
- the co-culture lysate has led to a significant improvement in CD4 and CD8 proliferative response in 3 out of 4 patients. This is indicative of a more representative spectrum of antigens being produced in co-culture than in the mono-culture of the DU-145 alone.
- the rat PA3 prostate tumour line is a relatively weak allogeneic immunogen in the copenhagen rat challenged with autologous MatLyLu prostate cells.
- PA3 rat prostate tumour cells grown in T185 flasks and PA3 cells co-cultured with bone stromal fibroblasts and YPEN endothelial cells in T185 flasks as a vaccine in a protection model.
- PA3 Clone 1 cells (1 x 10 6 ) cells were seeded into a T175 tissue culture flask in 35 ml of RPMI 1640 culture medium supplemented with 10% FCS/2 mM Glutamine. Cells were allowed to grow until confluent under conditions of 37°C/5% CO 2 . Confluent cells were harvested by washing the monolayer with 10ml Hank's buffered salt solution, followed by 5ml trypsin/EDTA solution to remove cells from the flask. Once all cells had lifted away from the flask surface the trypsin reaction was stopped by the addition of 5ml FCS. The 10ml of cell suspension was collected in a 50ml tube, centrifuged at 18,000 rpm for 3 minutes. The resultant pellet was re-suspended into 10ml PBS and stored on ice, prior to irradiation
- PA3 Clone 1 cells (1 x 10 5 ) and YPEN cells (1 x 10 5 ) were seed simultaneously into a T75 tissue culture flask containing 15ml RPMI 1640 culture medium supplemented with 10% FCS/2mM Glutamine. Cells were allowed to grow until confluent and harvested by cell scraping, pelleted by centrifugation at 18,000 rpm for 3 min, and re-suspended in 10ml PBS. Cells were stored on ice prior to irradiation.
- PA3 Clone 1 cells (1 x 10 5 ), YPEN cells 1 x 10 5 and RBMS (1 x 10 5 ) were seeded simultaneously into a T75 tissue culture flask containing 15ml RPMI 1640 culture medium supplemented with 10% FCS/2mM Glutamine. Cells were allowed to grow until confluent and harvested by cell scraping, pelleted by centrifugation at 18,000 rpm for 3 min, and re-suspended in 10ml PBS. Cells were stored on ice prior to irradiation.
- PA3 Clone 1 cells (1 x 105) and (1 x 105) RBMS were seeded simultaneouslyinto a T75 tissue culture flask containing 15ml RPMI 1640 culture medium supplemented with 10% FCS/2mM Glutamine. Cells were allowed to growuntil confluent and harvested by cell scraping, pelleted by centrifugation at 18,000 rpm for 3 min, and re-suspended in 10ml PBS. Cells were stored once prior to irradiation.
- Tubes containing cell suspensions were irradiated with 6 x 25 Gy (Total: 150 Gy). A cell count is then performed on each sample using a haemocytometer. Briefly 10 ⁇ l of each cell suspension in mixed with 90 ⁇ l of tryphan blue and approx. 10 ⁇ l was loaded under the coverslip of the haemocytometer. A cell count was performed using a x20 objective lens. Each cell suspension was then centrifuged at 18,000 rpm for 3 minutes. The resultant pellet was re-suspended into vaccine freezing medium (RPMI 1640/8%FCS/8%DMSO) at 5 x 10 6 cells per ml of freezing medium. Suspensions were then aliquoted into cryovials at 1.2ml per vial; vials were then placed into a -80°C freezer overnight prior to storage in liquid nitrogen.
- vaccine freezing medium RPMI 1640/8%FCS/8%DMSO
- the challenge material used for these experiments is the cell line Mat-Ly-Lu (Wild Type)
- Mat-Ly-Lu cells (1 x 10 6 ) were seeded into a T175 tissue culture flask in 35 ml of RPMI 1640 culture medium supplemented with 10% FCS/2 mM Glutamine. Cells were allowed to grow until confluent under conditions of 37°C/5% CO 2 . Confluent cells were harvested by washing the monolayer with 10ml Hank's buffered salt solution, followed by 5ml trypsin/EDTA solution to remove cells from the flask. Once all cells had lifted away from the flask surface the trypsin reaction was stopped by the addition of 5ml FCS. The 10ml of cell suspension was collected in a 50ml tube, centrifuged at 18,000 rpm for 3 minutes.
- the resultant pellet was re-suspended into 10ml PBS and stored on ice.
- a cell count was performed as detailed above and cell suspension adjusted to 5 x 10 5 per ml and aliquoted into cryovials at 1.2 ml per vial. Vials were then held on ice prior to injection.
- Irradiated Mat-Ly-Lu cells (0.2 ml) were injected into shaved left hind flank of a copenhagen rat. 1 vial is sufficient to inject 5 animals (1 experimental group). See below for injection regime for protection and therapy
- Tumor dimensions were collected using calipers, two measurements-longitudinal and transverse were taken for each tumor. These values were multiplied together to give an indication of tumor size. A kill size of 25 mm was set such that any tumor reaching size in one of the two measurable dimension was culled by exposure to a rising concentration of CO 2 and cervical dislocation. Kill curves were then generated.
- the rat PA3 prostate tumour line is a relatively weak allogeneic immunogen in the copenhagen rat challenged with autologous MatLyLu prostate cells.
- PA3 rat prostate tumour cells grown in 3D microgravity culture and PA3 cells co-cultured with bone stromal fibroblasts and YPEN endothelial cells in 3D microgravity culture as a vaccine in rat therapy and protection models.
- the roller cassette were filled with 35 ml culture medium (RPMI 1640 10% FCS/2mM Glutamine) through the screw cap, to this 6 x 10 6 cells suspended 6 ml of culture medium was added. The roller was then topped up to full (approx. 50ml) with -10 ml culture medium and the screw cap replaced. A 20ml syringe fitted with a 20 ⁇ m filter attached was screwed onto the outlet valve of the roller cassette. A second 20ml syringe fitted with a 20 ⁇ m was filled with culture medium and screwed onto the inlet valve of the roller cassette. Both valves on the cassette were opened and pressure applied to the inlet syringe to force any remaining air bubbles from within the cassette.
- 35 ml culture medium RPMI 1640 10% FCS/2mM Glutamine
- valves were closed and any remaining culture medium was aspirated off and the valves sealed with stoppers.
- the roller cassettes were attached to the roller apparatus and rotated at 16 rpm at 37°C/5% CO 2 . Cultures were allowed to continue for 3-4 days when they were harvested by unscrewing the cap on the roller and pouring the contents into a 50ml tube. The cells were washed three times by centrifugation and resuspension and stored on ice, prior to irradiation.
- the same growth methodology was used to produce co-cultures of PA3/YPEN, PA3/RBMS and PA3/YPEN/RBMS in 3D microgravity.
- the total seed into the 3D Cassette was retained at 6x10 6 cells (3x10 6 cells/cell type for two cell types or 2x10 6 cells /cell type for three cell types).
- the growth and harvest of the co-cultures is as described in the previous section.
- Tubes containing cell suspensions were irradiated with 6 x 25 Gy (Total: 150 Gy). A cell count is then performed on each sample using a haemocytometer. Briefly 10 ⁇ l of each cell suspension is mixed with 90 ⁇ l of tryphan blue and approx. 10 ⁇ l was loaded under the coverslip of the haemocytometer. A cell count was performed using a x20 objective lens. Each cell suspension was then centrifuged at 18,000 rpm for 3 minutes. The resultant pellet was re-suspended into vaccine freezing medium (RPMI 1640/8%FCS/8%DMSO) at 5 x 10 6 cells per ml of freezing medium. Suspensions were then aliquoted into cryovials at 1.2ml per vial; vials were then placed into a -80°C freezer overnight prior to storage in liquid nitrogen.
- vaccine freezing medium RPMI 1640/8%FCS/8%DMSO
- the challenge material used for these experiments is the cell line Mat-Ly-Lu (wild type).
- Mat-Ly-Lu cells(1 x 10 6 ) were seeded into a T175 tissue culture flask in 35 ml of RPMI 1640 culture medium supplemented with 10% FCS/2 mM Glutamine. Cells were allowed to grow until confluent under conditions of 37°C/5% CO 2 .
- Confluent cells were harvested by washing the monolayer with 10ml Hank's buffered salt solution, followed by 5ml trypsin/EDTA solution to remove cells from the flask. Once all cells had lifted away from the flask surface the trypsin reaction was stopped by the addition of 5ml FCS. The 10ml of cell suspension was collected in a 50ml tube, centrifuged at 18,000 rpm for 3 minutes. The resultant pellet was re-suspended into 10ml PBS and stored on ice. A cell count was performed as detailed above and cell suspension adjusted to 5 x 10 5 per ml and aliquoted into cryovials at 1.2 ml per vial. Vials were then held on ice prior to injection.
- Mat-Ly-Lu cells prepared as in the previous section were injected into shaved left hind flank of a copenhagen rat. 1 vial is sufficient to inject 5 animals (1 experimental group). See below for injection regime for protection and therapy
- Tumor dimensions were collected using calipers, two measurements-longitudinal and transverse were taken for each tumor. These values were multiplied together to give an indication of tumor size. A kill size of 25 mm was set such that any tumor reaching this size in one of the two measurable dimension was culled by exposure to a rising concentration of CO2 and cervical dislocation. Kill curves were then generated.
- Results for the comparison of 3D grown vaccines is shown in Figure 7.
- the 3D grown PA3 cells offer a good level of protection above that of the vehicle control.
- the 3D co-culture of PA3 with YPEN does not confer any protection and may reflect the reduction of PA3 cells as a mention previously .
- PA3 cells with RBMS also offer a good level of protection even though the level of PA3 is reduced compared to the PA3 alone vaccine.
- the co-culture of PA3/YPEN and RBMS provides slightly better protection than does the PA3 vaccine even though the PA3 contribution is probably three fold lower due to the seeeding level in the 3D culture. This would suggest that the co-culture of cell has resulted in an improved repertoire of antigens more reflective of the tumour in situ even though the vaccine is allogeneic.
- 10608 3868 0.36463 syntaxin 7 12068 6016 0.498508 ras-related protein RAB-32 5600 112 0.02 alcohol dehydrogenase class II pi subunit 5780 644 0.111419 peroxisomal bifunctonal enzyme 18800 10588 0.563191 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase; HMGCR) 6548 828 0.126451 apolipoprotein D precursor (apo-D) 13652 8300 0.60797 dihydrofolate reductase (DHFR) 15652 10956 0.699974 homolog of yeast D2-isopentenylpyrophosphate isomerase (IPP isomerase) 10036 1888 0.188123 LOX (Protein-lysine 6-oxidase, Lysyl-Oxidase) 15136 10044 0.663584 TIA-1 related protein; nucleolysin TIAR 5648
- microtubule-associated protein tau (MAPT); MTBT1 7540 1100 0.145889 PROTEIN PHPS1-2 7428 916 0.123317 epilepsy holoprosencephaly candidate-1 protein (EHOC-1); transmembrane protein 1 13184 6080 0.461165 DNA polymerase gamma (POLG); mitochondrial DNA polymerase Genes Up-Regulated in DU-145 / NHBSF Co-Culture Spot Intensity and Ratio DU-145/NHBSF Co-culture Ratio 3768 10280 2.728238 ESE1, ERT, JEN, ELF3 (Epithelial-specific transcription factor) 3732 13808 3.699893 Myelin-oligodendrocyte glycoprotein precursor (MOG) 19928 32924 1.652148 HLA-B-associated transcript 2; large proline-rich protein BAT2 2388 9900 4.145729 Complement 3 (C3) 6552 14756 2.252137 breakpoint
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (30)
- Vaccin contre le cancer à base de cellules complètes ayant :un composant immunogène qui comprend des cellules malignes et non malignes co-cultivées; etun véhicule, un excipient ou un diluant pharmaceutiquement acceptables.
- Vaccin à base de cellules complètes selon la revendication 1, dans lequel les cellules co-cultivées ont une immunogénicité modifiée.
- Vaccin à base de cellules complètes selon la revendication 2, dans lequel les cellules co-cultivées ont été cultivées dans des conditions qui n'étaient pas des conditions de culture 2D statique conventionnelle et dans lequel l'immunogénicité des cellules co-cultivées a été modifiée en comparaison à l'immunogénicité de cellules équivalentes co-cultivées dans des conditions de culture 2D statique conventionnelle.
- Vaccin contre le cancer à base de cellules complètes selon la revendication 2 ou 3, dans lequel l'immunogénicité modifiée est causée par la présentation de peptides sur des molécules MHC-1 des cellules non malignes.
- Vaccin contre le cancer à base de cellules complètes selon la revendication 1, dans lequel les cellules co-cultivées sont sous forme d'un sphéroïde.
- Vaccin à base de cellules complètes selon la revendication 5, dans lequel une ou plusieurs des cellules co-cultivées du sphéroïde, a/ont une immunogénicité modifiée.
- Vaccin à base de cellules complètes selon la revendication 6, dans lequel les cellules co-cultivées ont été co-cultivées sous microgravité et la ou chaque cellule co-cultivée a une immunogénicité modifiée comparée à des cellules équivalentes co-cultivées dans des conditions de culture 2D statique conventionnelle.
- Vaccin contre le cancer à base de cellules complètes selon la revendication 6 ou 7, dans lequel l'immunogénicité modifiée est causée par la présentation de peptides sur des molécules MHC-1 des cellules non malignes.
- Vaccin contre le cancer à base de cellules complètes selon l'une quelconque des revendications précédentes, dans lequel le composant immunogène comprend en plus un adjuvant.
- Vaccin à base de cellules complètes selon l'une quelconque des revendications précédentes, dans lequel les cellules non malignes sont autologues et les cellules malignes sont allogéniques.
- Vaccin contre le cancer à base de cellules complètes selon l'une quelconque des revendications précédentes, dans lequel les cellules malignes et/ou non malignes sont dérivées d'une lignée cellulaire.
- Procédé pour produire un vaccin contre le cancer à base de cellules complètes qui comprend :co-cultiver des cellules malignes et non malignes;récolter les cellules co-cultivées;ajouter les cellules co-cultivées récoltées à un véhicule, excipient ou diluant pharmaceutiquement acceptables.
- Procédé selon la revendication 12, dans lequel les cellules sont co-cultivées dans des conditions qui ne sont pas des conditions de culture 2D statique conventionnelle.
- Procédé selon la revendication 13, dans lequel les cellules sont co-cultivées dans des conditions de culture non adhérentes.
- Procédé selon la revendication 14, dans lequel les cellules sont co-cultivées dans des récipients de culture non adhérents.
- Procédé selon la revendication 13, dans lequel les cellules sont co-cultivées dans des conditions de culture non statiques adhérentes.
- Procédé selon la revendication 16, dans lequel les cellules sont co-cultivées dans des flacons de culture roulants.
- Procédé selon la revendication 13, dans lequel les cellules sont co-cultivées sous microgravité.
- Procédé selon la revendication 18, dans lequel les cellules forment des sphéroïdes sous microgravité et les sphéroïdes sont récoltés et ajoutés au véhicule, excipient ou diluant pharmaceutiquement acceptables.
- Procédé selon la revendication 13, dans lequel les cellules sont co-cultivées sur des micro-supports mis en suspension dans un milieu de culture.
- Procédé selon la revendication 20, dans lequel les micro-supports sont des perles ou des disques en fibres non tissées.
- Procédé selon l'une quelconque des revendications 12 à 21, dans lequel co-cultiver les cellules modifie leur immunogénicité.
- Procédé selon la revendication 22, dans lequel l'immunogénicité des cellules est modifiée en comparaison à des cellules équivalentes co-cultivées dans des conditons de culture 2D statique conventionnelle.
- Procédé selon la revendication 22 ou 23, dans lequel l'immunogénicité modifiée est causée par la présentation de peptides sur des molécules MHC-1 des cellules non malignes.
- Procédé selon l'une quelconque des revendications 12 à 24, dans lequel les cellules non malignes sont autologues et les cellules malignes sont allogéniques.
- Procédé selon l'une quelconque des revendications 12 à 25, dans lequel les cellules malignes et/ou non malignes sont dérivées d'une lignée cellulaire.
- Procédé selon l'une quelconque des revendications 12 à 26 comprenant en plus l'irradiation gamma des cellules co-cultivées.
- Procédé selon l'une quelconque des revendications 12 à 27, dans lequel les cellules comprennent l'un ou les deux de ECACC 00032802 et de ECACC 00032801.
- Vaccin selon l'une quelconque des revendications 1 à 11, dans lequel les cellules comprennent l'un ou les deux de ECACC 00032802 et de ECACC 00032801.
- Vaccin selon l'une quelconque des revendications 1 à 11 et 29, dans lequel le cancer à traiter est un cancer de la prostate.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911823.4A GB9911823D0 (en) | 1999-05-21 | 1999-05-21 | New vaccine formulations |
GB9911824 | 1999-05-21 | ||
GB9911823 | 1999-05-21 | ||
GBGB9911824.2A GB9911824D0 (en) | 1999-05-21 | 1999-05-21 | New vaccine formulations |
GB0008032 | 2000-04-01 | ||
GB0008029 | 2000-04-01 | ||
GB0008029A GB0008029D0 (en) | 2000-04-01 | 2000-04-01 | New vaccine formulations |
GB0008032A GB0008032D0 (en) | 2000-04-01 | 2000-04-01 | New prostate cell lines |
PCT/GB2000/001918 WO2000071155A2 (fr) | 1999-05-21 | 2000-05-19 | Nouvelles formulations vaccinales -2 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1178822A2 EP1178822A2 (fr) | 2002-02-13 |
EP1178822B1 true EP1178822B1 (fr) | 2004-02-18 |
Family
ID=27447826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00931400A Expired - Lifetime EP1178822B1 (fr) | 1999-05-21 | 2000-05-19 | Vaccin anticancereux a cellules entieres comprenant des cellules malignes et non-malignes co-cultivees |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1178822B1 (fr) |
JP (1) | JP2003500366A (fr) |
KR (1) | KR20020027318A (fr) |
AT (1) | ATE259655T1 (fr) |
AU (1) | AU4935600A (fr) |
CA (1) | CA2374294A1 (fr) |
DE (1) | DE60008368T2 (fr) |
ES (1) | ES2215662T3 (fr) |
WO (1) | WO2000071155A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60144515D1 (de) * | 2000-04-01 | 2011-06-09 | Onyvax Ltd | Prostata zellinien und deren verwendung |
US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
WO2011129348A1 (fr) * | 2010-04-13 | 2011-10-20 | 株式会社Reiメディカル | Composition pour le traitement du cancer, qui est produite à partir d'une masse cellulaire p ou d'un agrégat de cellules cancéreuses, et procédé de production d'un agent immunothérapeutique et procédé d'évaluation de l'efficacité de l'immunothérapie utilisant tous deux la composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69627527T2 (de) * | 1995-12-28 | 2004-03-04 | The Johns Hopkins University School Of Medicine | Allogene parakrine cytokine tumor impfstoffe |
US6982168B1 (en) * | 1996-02-02 | 2006-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
US5804443A (en) * | 1997-02-28 | 1998-09-08 | Bernofsky; Carl | Human monocytic leukemia cell line |
AU9794698A (en) * | 1997-10-10 | 1999-05-03 | Regents Of The University Of California, The | Enhanced immunogenic cell populations prepared using h2 receptor antagonists |
-
2000
- 2000-05-19 KR KR1020017014806A patent/KR20020027318A/ko not_active Application Discontinuation
- 2000-05-19 CA CA002374294A patent/CA2374294A1/fr not_active Abandoned
- 2000-05-19 EP EP00931400A patent/EP1178822B1/fr not_active Expired - Lifetime
- 2000-05-19 DE DE60008368T patent/DE60008368T2/de not_active Expired - Fee Related
- 2000-05-19 AU AU49356/00A patent/AU4935600A/en not_active Abandoned
- 2000-05-19 JP JP2000619457A patent/JP2003500366A/ja active Pending
- 2000-05-19 WO PCT/GB2000/001918 patent/WO2000071155A2/fr not_active Application Discontinuation
- 2000-05-19 ES ES00931400T patent/ES2215662T3/es not_active Expired - Lifetime
- 2000-05-19 AT AT00931400T patent/ATE259655T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60008368D1 (de) | 2004-03-25 |
WO2000071155A3 (fr) | 2001-02-22 |
EP1178822A2 (fr) | 2002-02-13 |
AU4935600A (en) | 2000-12-12 |
ATE259655T1 (de) | 2004-03-15 |
KR20020027318A (ko) | 2002-04-13 |
JP2003500366A (ja) | 2003-01-07 |
CA2374294A1 (fr) | 2000-11-30 |
ES2215662T3 (es) | 2004-10-16 |
WO2000071155A2 (fr) | 2000-11-30 |
DE60008368T2 (de) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2084267B1 (fr) | Vaccins comprenant des antigenes de cellules souches cancereuses et procedes | |
EP2009097A1 (fr) | Cellules souches de prostate normale | |
JP4607330B2 (ja) | ガンの新規処置 | |
CN101855339A (zh) | 人类癌症干细胞 | |
AU2002365291A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
JP5762738B2 (ja) | 細胞株、黒色腫の治療のためにそれを含む組成物、組成物の製造手順および治療方法 | |
Abdel-Wahab et al. | Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity | |
US20140234350A1 (en) | Ovarian cancer vaccines and vaccination methods | |
JP2002539805A5 (fr) | ||
US8691568B2 (en) | Method for preparing cell populations with anti-tumor immune response activity | |
CN115698270A (zh) | 一种通过iPS细胞生产再生T细胞的方法 | |
JP4949554B2 (ja) | ガンの新規処置 | |
JP2000506379A (ja) | ヒト前立腺上皮不死細胞の細胞株およびクローンおよびそれらの研究および前立腺癌治療に対する応用 | |
EP1178822B1 (fr) | Vaccin anticancereux a cellules entieres comprenant des cellules malignes et non-malignes co-cultivees | |
CN113444687A (zh) | 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法 | |
EP1930427B1 (fr) | Peptide derive d antigene de carcinome a cellules squameuses se liant a la molecule hla-a24 | |
CN109371005B (zh) | 一种hla-0201限制性padi4表位多肽及其应用 | |
EP1017815A1 (fr) | Modele murin associe a un carcinome humain | |
EP1272617B1 (fr) | Lignees cellulaires prostatiques | |
EP1178823A2 (fr) | Nouvelles preparations vaccinales - 1 | |
WO2005026326A2 (fr) | Generation de lignees cellulaires de poulet a partir de cellules souches et de cellules germinales embryonnaires | |
Jian et al. | Optimal conditions for adenoviral transduction of immature dendritic cells without affecting the tolerogenic activity of DC-based immunotherapy | |
ES2367006T3 (es) | Estirpes celulares de prostata y su uso. | |
WO2000071156A2 (fr) | Nouvelles formulations vaccinales-3 | |
JP2002238552A (ja) | ヒト血清アルブミンを用いたヒト末梢血単核球であるcd14+細胞からの樹状細胞の調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011203 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20030326 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: WHOLE CELL CANCER VACCINE COMPRISING CO-CULTURED MALIGNANT AND NON-MALIGNANT CELLS |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040218 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040218 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040218 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60008368 Country of ref document: DE Date of ref document: 20040325 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040518 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040518 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: ONYVAX LIMITED |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: ONYVAX LIMITED Free format text: ONYVAX LIMITED#ST. GEORGE'S HOSPITAL MEDICAL SCHOOL, CRANMER TERRACE, P.O. BOX 17717#LONDON SW17 0RE (GB) -TRANSFER TO- ONYVAX LIMITED#ST. GEORGES HOSPITAL MEDICAL SCHOOL#LONDON SW17 0RE (GB) Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20040218 |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: ONYVAX LIMITED |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2215662 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20041119 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20050503 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20050511 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20050517 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060531 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20061201 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040718 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20080522 Year of fee payment: 9 Ref country code: ES Payment date: 20080619 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20080527 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080521 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20081128 Year of fee payment: 9 |
|
BERE | Be: lapsed |
Owner name: *ONYVAX LTD Effective date: 20090531 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090519 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090602 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20080514 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090531 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091201 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090520 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090520 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090519 |